Management of Persistent Hyperlipidemia in Diabetic Patients

Introduction to Lipid Management

The American College of Cardiology recommends adding ezetimibe 10 mg daily to the current atorvastatin 80 mg regimen for patients with diabetes and established cardiovascular disease equivalent who have failed to achieve the target LDL-C <70 mg/dL on maximally tolerated statin monotherapy 1, 2
Diabetes is considered a coronary heart disease (CHD) risk equivalent, placing patients in the very high-risk category with an LDL-C goal of <70 mg/dL, according to the American Heart Association and the American Diabetes Association 3, 4, 1

Each 38.7 mg/dL reduction in LDL-C reduces cardiovascular events by approximately 28%, making further reduction critical, as stated by the American College of Cardiology 1, 2
Current LDL-C levels of 154 mg/dL represent treatment failure on atorvastatin 80 mg, which should achieve approximately 50% LDL-C reduction, according to the American College of Cardiology 2

The American College of Cardiology recommends starting ezetimibe 10 mg daily in addition to continuing atorvastatin 80 mg, with an expected additional LDL-C reduction of 15-25% 1, 2, 5
Reassess lipid panel in 4-12 weeks to evaluate response, as recommended by the American College of Cardiology and the American Association of Clinical Endocrinologists 5

The primary target is LDL-C <70 mg/dL, according to the American College of Cardiology and the American Heart Association 1, 5
Secondary targets include non-HDL-C <100 mg/dL and triglycerides <150 mg/dL, as recommended by the American Heart Association and the American Diabetes Association 3, 4
Recheck lipid panel 4-12 weeks after adding ezetimibe and continue monitoring every 3-12 months once at goal, as recommended by the American College of Cardiology and the American Association of Clinical Endocrinologists 5

Ezetimibe has an excellent safety profile when combined with statins, with no significant increase in myopathy risk, according to the American College of Cardiology 1
Continue monitoring for statin-related adverse effects, but these are not contraindications to adding ezetimibe, as stated by the American College of Cardiology and the American Association of Clinical Endocrinologists 2